Debate exists regarding the role of roboticassisted surgery in colorectal cancer. Robotic-assisted surgery has been promoted as a strategy to increase the availability of minimally invasive surgery, which is associated with improved short-term morbidity; however, robotic-assisted surgery is much more expensive than laparoscopic surgery.
l aparoscopic surgery has gained widespread acceptance for resection of colorectal cancer (CRC), with better short-term complication rates and similar long-term outcomes relative to conventional open surgery. 1, 2 in 2000, the da Vinci surgical system was approved by the us food and Drug administration as a commercially available tool for robotic surgery. Robotic surgical devices allow a surgeon at a console to operate remotecontrolled robotic arms to facilitate the performance of complex minimally invasive surgery (mis). advantages of robotic surgical devices that address limitations of traditional laparoscopy include improved dexterity, avoidance of a fulcrum effect, stable camera platform and improved 3-dimensional imaging, motion scaling, and improved physician ergonomics. some of these advantages may be especially important in specific types of surgery, such as surgery in confined spaces for prostate or rectal cancer. [3] [4] [5] use of the system has been proven to be safe and feasible but may be more time consuming and is more expensive, without any proven clinical advantages over conventional laparoscopy for CRC. 6, 7 in an era where a changing healthcare system forces optimization of resource use and critical consideration of every dollar spent on health care, the value of robot-assisted surgery (Ras) merits examination. 6 Despite a lack of convincing evidence of superiority of the robot-assisted approaches in CRC, the use of Ras appears to be increasing. many hospitals in the united states have installed robotic systems. hospitals acquire new technology for many reasons, such as the desire to improve clinical care and patient outcomes, competitive pressure from nearby hospitals resulting from the fear of being left behind in important developments, profit seeking, and the availability of capital to adopt new technologies. early adopters of new technologies (eg, Ct colonography and advanced imaging) tend to be teaching hospitals, hospitals with higher patient volumes, and hospitals located in areas with higher average incomes. 8, 9 information about the types of hospitals that are early adopters in the use of robotic surgery is lacking.
Robotic surgical systems have high fixed (capital) costs, ranging from $1.0 to $2.5 million per unit. the use of robotics also adds significant cost per procedure compared with conventional laparoscopy because of longer operative times and expensive disposable equipment. 10 this additional hospital spending is likely to affect the expenditures of public and private insurers. 10 the use of new technology in medicine has historically outpaced the availability of data to support its rapid adoption. the process of diffusion of an innovation (eg, new technology) can be illustrated by graphing its cumulative uptake over time.
11 this diffusion curve typically displays an s-shaped distribution: early in the diffusion process few individuals adopt or receive the innovation, the rate of uptake then accelerates, and finally it increases at a slower rate as fewer and fewer remaining potential individuals adopt or receive it. however, innovations often diffuse at different rates among subgroups in the population. in some instances, the availability of new technology may initially increase health disparities resulting from the types and location of hospitals acquiring this technology and characteristics of patients who have access to them for various reasons. 12 in urologic surgery, where robotic surgery is used in >50% of radical prostatectomies, access is greater among whites, those who live in more affluent areas, and in teaching hospitals. 13 the use and potential disparities associated with availability and acquisition of robot-assisted devices for patients diagnosed with colon or rectal cancer are largely unknown. the diffusion of Ras may be different from other technologies that have been proven to be effective.
our purpose was to describe the availability in 2010 and acquisition by 2012 of robotic systems across us hospitals using american hospital association (aha) data and characteristics of patients diagnosed with malignancies of the colon and rectum who received Ras using the 2008-2012 nationwide inpatient sample. Knowledge of the adoption patterns will help policymakers estimate the financial impact of this technology and will help clarify whether Ras has increased access to lower-morbidity mis for patients with CRC.
PATIENTS AND METHODS

AHA Data
Data were obtained from the 2010 and 2012 aha annual cross-sectional survey to describe the availability and acquisition of robotic systems. this annual survey is mailed to all hospital chief executive officers in the united states, asking them to circulate it to the individuals most appropriate to complete different sections. the survey provides a cross-sectional view of us hospitals and collects data about hospital size, ownership, geographic location, services offered, and staffing. We limited our analysis to hospitals that were classified as general medical and surgical, surgical, cancer, chronic disease, or other specialty hospitals that completed the survey. the response rate among these hospitals was 80.0% in 2010 and 80.2% in 2012.
the aha survey asks respondents to check a box if robotic surgery, defined as the use of mechanical guidance devices to remotely manipulate surgical instrumentation, is provided by the hospital or its subsidiary. Respondents are instructed to leave the box blank if the service is not provided. We examined whether hospitals offered Ras in 2010 and if hospitals newly acquired this technology between 2010 and 2012.
We selected characteristics of hospitals from the 2010 aha data that were adopters of Ras based on studies that examined adoption of new imaging tests (64-section Ct and Ct colonography). 8, 9 We included data about hospital ownership; size, based on total annual inpatient surgical operations; teaching status, as determined by membership in the Council of teaching hospitals and health systems; membership in the cancer program approved by american College of surgeons; implementation of an electronic health record; provision of oncology services; and having a medical/surgical intensive care unit. We also included whether hospitals were members of hospital systems, because these hospitals may have different technologyadoption decision-making processes than free-standing hospitals and may have access capital more readily. location of hospitals was based on 10 state census divisions (core-based statistical areas) and whether hospitals were located in metro, micro, division, or rural counties. as a measure of early adoption of new technology, we summed the number of new imaging tests offered at each hospital (range, 0-5), including multisection spiral computed Ct 64, positron emission tomography, positron emission tomography/Ct, single photon emission Ct, and virtual colonoscopy (Ct colonography). We also included whether hospitals had plans to develop, execute, or evaluate diversity strategies or plans and calculated point distance to the nearest hospital with Ras as a measure of local competitiveness using arcGis (esri, Redlands, Ca). We used multivariable logistic regression to calculate oRs and 95% Cis to identify predictors of hospital Ras adoption between 2010 and 2012. hospitals that already adopted Ras by 2010 were excluded in this analysis of hospital Ras adoption.
Nationwide Inpatient Sample
Data (2010-2012) were obtained from the nationwide inpatient sample to identify characteristics of patients with CRC who were diagnosed with malignancies of the colon and rectum and received Ras.
14-16 the 2010-2011 nis is a nationally representative sample of ≈20% of us hospitals, resulting in a sampling frame of 97% of all discharges. approximately 1000 hospitals contributed data to the nis during 2010 and 2011. in 2012, the nis was redesigned as a sample of discharges from all hospitals. Data elements in the 2010-2012 nis are drawn from hospital discharge abstracts regarding admission, patient demographics and location, payer, diagnosis and procedures, and hospital characteristics.
We limited discharge data to patients with CRC who underwent elective laparoscopic or open colon or rectal surgery during 2010-2012 as identified from International Classification of Disease, Ninth Revision, Clinical Modification (iCD-9-Cm) codes. We used iCD-9-Cm diagnostic code 153.x to identify colon cancer and 154.0, 154.1, 154.2, and 154.8 to identify rectal cancer. 17 We used iCD-9-Cm procedure codes to identify laparoscopic sur- 17, 18 We used iCD-9-Cm procedures code 17.4x to identify robot-assisted cases. 17, 19 We included patient race, sex, location of residence (national Center for health statistics rural-urban code, median household income in patient zip code), expected primary payer, diagnosis related group-based mortality risk, and year of admission. We used the all Patient Refined Diagnosis Related Group mortality risk algorithm as a surrogate marker of disease severity. 20 this algorithm (mild, moderate, severe, and extreme) is based on patient age, diagnosis, and procedure codes and has high predictive validity. 21 We constructed a hospital-level variable describing the number of robotic surgeries for non-CRC diagnoses. Because ≈75% of hospitals did not bill for any robotic surgery, we constructed 4 groups of hospitals, including 0 robotic surgeries, 1 to 59 surgeries, 60 to 180 surgeries, and 181 or more robotic surgeries (per 3 years).
We used multivariable logistic regression to calculate oRs and 95% Cis to identify factors predictive of Ras use, incorporating recommended discharge weights, resulting in national estimates for all of the analyses. all of the statistical analyses for the aha and nis databases were conducted using sas version 9.4 (sas institute, Cary, nC) and stata 13.1 (stata Corp, College station, tX). statistical significance was set at p < 0.05, and all of the tests were 2 sided. adjusted analysis showed that teaching hospitals; hospitals that offered more advanced imaging services; hospitals located in east, south Central, or mountain states; and those where staff performed the largest volume of inpatient surgeries were more likely to acquire Ras technology between 2010 and 2012 than their respective counterparts (table 1). hospitals that were located in micropolitan or rural areas were less likely to acquire Ras technology than metropolitan hospitals. state or local hospitals were less likely to acquire Ras technology by 2012 compared with nongovernment nonprofit hospitals. hospital characteristics not predictive of Ras acquisition by 2012 included accreditation by the american College of surgeons, implementation of electronic health records, oncology service provision, diversity plan, distance to the nearest hospital with Ras, and being part of a hospital network. model fit was excellent (c-statistic = 0.87; hosmer and lemeshow goodness-of-fit p = 0.3174).
RESULTS
Hospital Availability of RAS in
Because of its prominence in the model, we examined the influence of the number of inpatient surgeries on our findings by comparing logistic models with and without this variable. the c-statistic was slightly higher for a model with this variable (c-statistic difference = 0.02; p < 0.01). accreditation by the american College of surgeons, providing oncology services, and having a medical/surgical intensive care unit were predictors of Ras adoption by hospitals in a model without the number of inpatient surgeries, but these variables were no longer predictive of Ras adoption when the number of surgeries was included in the model. this suggests that the number of inpatient surgeries in 2010 was a key driver of adoption of Ras by 2012 among hospitals accredited by the american College of surgeons, those providing oncology services, and those having a medical/ surgical intensive care unit. overall, only 1.3% of patients with CRC received Ras during 2010-2012, which increased over time from 0.7% in 2010 to 1.3% in 2011 to 2.0% in 2012 (p < 0.001). an estimated 1935 Rass (95% Ci, 1573-2296) in patients with CRC were performed nationally, ranging from 0 to 60 surgeries across hospitals. of all of the robotic surgeries for rectal cancer, 72% were performed at hospitals with the highest volume of robotic surgeries. this number was 79% for colon cancer. the percentage of patients with CRC who were treated robotically among those undergoing mis increased over time from independent factors predicting Ras use included type of cancer, mortality risk, year of admission, and the interaction between year of diagnosis and type of cancer. Patients were less likely to receive Ras if they had higherthan-moderate diagnosis related group-related mortality risk (table 4) . the use of Ras increased in 2011 and 2012 relative to 2010 for patients with colon cancer. the use of Ras was only increased in 2012 for patients with rectal cancer relative to 2010 (not in 2011 versus 2010). Ras use was unaffected by patient race, sex, insurance type, or median income of the zip code of residence. the predicted percentage of patients with CRC receiving Ras ranged from 0.1% to 15.2% (mean = 1.4%), suggesting wide vari- 
RAS Use Among Patients
DISCUSSION
the united states leads the world in creating healthcare technologies. although many advances have substantially improved health at modest cost, 22 other technologies, including robotic surgery, have increased spending without producing demonstrable gains in health. in this study, we find that, by 2012, >25% of hospitals had adopted Ras in the united states, suggesting that Ras adoption has now moved beyond the tipping point of ≈20% toward widespread implementation.
11 our results are consistent with other studies finding that early adopters of new technologies tend to be teaching hospitals and those with higher patient volumes. 9 Distance to the nearest hospital with Ras did not affect the adoption of Ras locally, suggesting that marketing and local competition play lesser roles compared with the number of inpatient surgeries. one of the goals of this study was to understand the specific use of Ras for CRC, an arena in which there are clearly lower short-term complication rates for mis. Despite Ras not being superior to laparoscopic surgery for CRC, 1 advantage of Ras might be that it may expand access to mis surgery to patients with CRC who might otherwise have open surgery as their only option. in this study we found that Ras for rectal cancer (but not for colon cancer) increased disproportionately to laparoscopic surgery. this suggests that Ras may be resulting in more overall mis for rectal cancer rather than just exchanging an older technology for a more expensive one.
in contrast to urologic surgery, where robotic surgery is used in >50% of radical prostatectomies, 13, 19 the overall use of Ras in patients with CRC remains low, especially for colon cancer, where laparoscopic surgery is well established and technically feasible for most patients. however, for the more technically challenging operations for rectal cancer, Ras increased rapidly from 5.5% in 2010 to 13.3% in 2012 (whereas laparoscopic use increased only from 33.5% in 2010 to 38.1% in 2012). these results may suggest that Ras is being adopted for CRC in a more thoughtful way compared with its rapid adoption across the board in areas such as hysterectomy. 23 however, conversion from mis to open surgery in rectal cancer is still a significant issue.
Certain groups of patients have less access to new technology, especially rural patients and those of lower socioeconomic status. this study confirms differential access to Ras for rural and urban patients, but this was explained by the number of robotic surgeries performed for non-CRC. no patient-level differences by race, income, or insurance were found. however, if it is the case that sur- geons are reserving Ras for more challenging cases, it is surprising that our study finds that use is equally applied for men and women, given that rectal cancer surgery is usually more technically challenging for patients who are men. this suggests that perhaps individual surgeons adopt a single platform for rectal cancer surgery (open, laparoscopy, or robotic) and then use it for all cases. this study is limited by its observational nature. this includes some limitations pertaining to the nis database, such as limited availability of clinical data, possible bias from coding inaccuracies, an inability to show complete episode of care, lack of representation of all hospital types, and lack of information on revenue or cost. the data also underestimate the total number of discharges because they do not include federal hospitals. the Current Procedural terminology code for Ras also does not distinguish between single-site and other Ras platforms. also, we do not have information about who completed the aha survey at the hospitals. it is possible that the individual completing the survey may not have known whether the hospital provides Ras, particularly if the service was recently added. no data were available in the aha survey about the number of prostatectomies, which likely account for the majority of robotic procedures. finally, the acquisition of additional robotic systems among hospitals with Ras was unable to be determined from the aha survey data.
CONCLUSION
future increases in healthcare spending could be moderated if costly new medical services such as Ras are adopted more selectively. it appears that, for patients with CRC, Ras is in fact being adopted more thoughtfully for the more challenging subset of rectal cancer cases and not for colon cancer cases. nevertheless, there is wide variation in the use of this technology that likely is related to market forces, and there is still a great deal of variation in access to mis for CRC across patients and hospitals. 
